cell and gene therapy catapult annual report

The Cell and Gene Therapy Catapult (CGT Catapult) today released new data in their 2020 Cell and gene therapy GMP manufacturing in the UK: capability and capacity analysis report, which shows progress of the industry towards commercialisation of therapies with further growth across a number of indicators including facilities, manufacturing space, and personnel. In their 2019 Annual Review, Cell and Gene Therapy Catapult (CGT Catapult, London, UK) discuss how they have supported the development of the cell and gene therapy industry over the last 12 months. The reports published by our team are designed to give insight into the work we undertake at ORE Catapult, both in terms of our own research activities and for our stakeholders, as well as the impact our activities have on our industry. ORE Catapult. Open to Oxford University researchers and spin outs developing technologies in cell and gene therapy. The Energy Data Taskforce, commissioned by Government, Ofgem, and Innovate UK, has set out five key recommendations that will modernise the UK energy system and drive it towards a net zero carbon future through an integrated data and digital strategy throughout the sector.. These therapies are now getting to patients and Innovate UK is looking forward to continue to support the Cell and Gene Therapy Catapult and its initiatives such as its skills programme and Advanced Therapy Treatment Centres. US Pharmacopeia Standards for Cell and Gene Therapy mRNA Standards Standard for T7 RNA polymerase activity – Could be in “kit” with NTPs, template – Template choice (length, composition) up for discussion mRNA product in a vial at a defined concentration (1mg/mL) to standardize dose determining assays mRNA size standards across a range, e.g. 20.07.20. annual review. The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT. News. In this infographic, we present some of the highlights from the report. ... Energy Systems Catapult’s mission is to unleash innovation and open new markets to capture the clean growth opportunity. Report shows number of facilities and highly-skilled jobs rises . The CGT Catapult, the UK's cell and gene therapy accelerator, has released its annual review 2019. Cell and Gene Therapy Catapult highlights sector growth in Annual Review, Catapult Cell and Gene TherapyWe work with innovate UK, Advanced Therapies Apprenticeship Community, Press release: Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry, Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients, Annual Review 2018 highlights work of the Cell and Gene Therapy Catapult in building the world’s most complete advanced therapies ecosystem, Press Release: Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector, Press release: Investment in the cell and gene therapy industry in the UK grows 10x since 2012 to £400m/year, Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review, Publication of Cell Therapy Catapult’s First Review. Cost Reduction Monitoring Framework (CRMF): ORE Catapult report to the OWPB . British cell and gene therapy accelerator releases annual report. www.ct.catapult.org.uk. Cell and Gene Therapy Catapult. Moving forward, we strive to continue our mission to create more high value employment and make more life-changing therapies a therapeutic reality for patients around the world. READ REPORT > TiPTORS Phase 1 ‘DfR’ specification . NEWS. Cell and Gene Therapy Catapult – Written evidence (CAT0001) The contribution of innovation Catapults to delivering the R&D Roadmap An introduction to cell and gene therapies and the role of the Cell and Gene Therapy Catapult Cells, each of which contain our full genetic information, are the building blocks for complex life. “The data in the 2016 report shows growth across all the markers that we analyse and forecasts a considerable increase again in the next 12 months. The review summarises the capability and capacity of all cell and gene therapy manufacturing facilities in the UK that hold an MHRA-license. The CGT Catapult has worked on more than 110 projects addressing industry challenges . view. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Oct 2020 UK-Taiwan Technology Showcase for Compound Semiconductors: Power Electronics for Net Zero . We have the infrastructure and a team of specialists across the cell and gene therapy life cycle, who will work with you when you need us, to enable you to get the best possible results. It also contains a statement from the outgoing Chair Andy Green and thoughts from Juergen Maier, the incoming Chair of Digital Catapult. The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies. Activities. Offshore Renewable Energy. Ian Muir, Director – Healthcare & Life Sciences, Innovate UK. Compound Semiconductor Applications Catapult is a company limited by guarantee. The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies. Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients. Topics and Learning Objectives: 1. With cell therapy, cells are cultivated or modified outside the body before being injected into the patient. The reports published by our team are designed to give insight into the work we undertake at ORE Catapult, both in terms of our own research activities and for our stakeholders, as well as the impact our activities have on our industry. The CGT Catapult has worked on more than 110 projects addressing industry challenges . VAT number 154 4214 33. 16-Jul-2019 . British cell and gene therapy accelerator releases annual report. Medicines in Development: Cell Therapy and Gene Therapy ǀ 2020 12. Thu … READ REPORT > “This latest report published by the Cell and Gene Therapy Catapult demonstrates our important place in this dynamic and rapidly growing industry. The Annual Engagement & Impact Report provides details of these programmes, which span AI, Immersive and Future Networks technologies with a focus on the creative and manufacturing industries. In this infographic, we summarize CGT Catapult’s 2018—2019 highlights. Now, in the Catapult's 2020 report, it has shown that its GMP manufacturing space has expanded by 48% - despite the pandemic. Stevenage already has the largest cell and gene therapy cluster outside of the US. The Cell and Gene Therapy Catapult (CGT Catapult) has today published its Annual Review 2020, highlighting achievements and initiatives from the past year which are enhancing growth and productivity in the UK cell and gene therapy industry. Cell And Gene Therapy Definitions For Raw Materials, Starting Materials, Drug Substance And Drug Product The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials, process intermediates, drug substance and drug products. We do this by championing innovative life science technology and new approaches, supporting UK innovators to succeed. Acquisition transfers intellectual property and commercialisation rights to promising cancer immunotherapy; Further development will take place at the Cell and Gene Therapy Catapult UK manufacturing centreThe Cell and Gene Therapy Catapult (CGT Catapult) today announced the sale of its subsidiary, Catapult Therapy TCR Ltd, to Cell Medica. CGT Catapult brings SMEs together. UK Prime Minister, Boris Johnson, visited ORE Catapult at Blyth today (Friday 11 December 2020). It has been another year of progress for the UK cell and gene therapy industry, with 12% of global advanced therapy medicinal product (ATMP) clinical trials taking place in the UK, with over 3,000 jobs created in the sector, and over 90 advanced therapy developers currently based in the UK. Cancer Drug Name Sponsor Indication Development Phase AIC100 AffyImmune Therapeutics thyroid cancer Phase I (ICAM-1 CAR-T cell therapy) Natick, MA ORPHAN DRUG ALLO-501 Allogene Therapeutics large B-cell follicular lymphoma Phase I/II The difference between cell therapy and gene therapy: Cell therapy aims to treat diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body 5. UK Prime Minister, Boris Johnson, visited ORE Catapult at Blyth today (Friday 11 December 2020). Annual Report Summary 2018/19 . Energy Systems Catapult is an independent, not-for-profit organisation that contributes unique whole systems evidence through Insight Papers and Reports, to help industry and government make decisions that unleash innovation, transform the energy system and open new markets to … ORE Catapult. The recommendations highlight that to move towards a ‘Modern, Digitalised Energy System’ is being hindered by often poor quality, inaccurate, or missing data, while valuable data is often restricted or hard to find. The review summarizes the capability and capacity of all cell and gene therapy manufacturing facilities in the UK that hold an MHRA-licence. CGT Catapult brings SMEs together. The Cell and Gene Therapy Catapult Manufacturing Innovation Centre is due to open in December 2021. Medicines Discovery Catapult (MDC) is enabling the community to reshape medicines discovery in the UK. Join ARM for the organization’s annual Cell & Gene State of the Industry Briefing, a top-level gathering for key stakeholders in the field. The Energy Data Taskforce, commissioned by Government, Ofgem, and Innovate UK,has set out five key recommendations that will modernise the UK energy system and drive it towards a net zero carbon future through an integrated data and digital strategy throughout the sector. 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. This world-leading centre will bring manufacturing of pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres. Annual Impact Review 2019-2020. The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. Report shows number of facilities and highly-skilled jobs rises . This event will include ARM’s annual yearly update on the sector’s progress followed by a panel session featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year. This reduction in booked capacity is likely indicative of projects at these sites coming to … Wednesday 21 October 2020, 13.00-15.00. The Catapult Network 2019-2020 Annual Report. Read the full Annual Report here […] It is playing a vital role in growing the UK cell and gene therapy industry, placing the UK in a world leading position, helping companies to grow. For comprehensive news update, please visit the individual Catapult websites. Call us +44 (0) 203 728 9500. For instance, since November 2017 the UK has seen a 60% increase in manufacturing space for cell and gene therapies. Cell and Gene Therapy. Joanna Partridge. We are encouraged to see the global standing of our sector highlighted by agreements in leading advanced therapy countries, like the US and Japan, along with highly innovative collaborators in the UK, from fledgling biotechs to big pharma giants. HESI’s Cell Therapy–TRAcking, Circulation, & Safety (CT-TRACS) Committee is honored to have presented the first workshop of the new Cell and Gene Therapy Catapult seminar series. +44(0)20 3728 9500 ct.catapult.org.uk The Cell and Gene Therapy Catapult UK Future needs in patient safety of cell-based therapies. British cell and gene therapy accelerator releases annual report. Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector. Registered in England and Wales with company number 10255214. Photograph: Igor Golovniov/SOPA Images/Rex/Shutterstock. CGT Catapult engages academic hubs to support translation of research . The Cell and Gene Therapy Catapult manufacturing centre is a crucial component of the industrial strategy and part of the leading-edge healthcare technology challenge fund. Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Initially a one-off review in 2013, this review is now an important annual undertaking CGT Catapult initiatives have also made a significant impact in the industry over the past twelve months: Matthew Durdy, CEO, Cell and Gene Therapy Catapult. You can access the Cell and Gene Therapy Catapult 2019-20 Annual review at: ct.catapult.org.uk/annualreviews, Catapult Cell and Gene TherapyWe work with innovate UK, Advanced Therapies Apprenticeship Community, Press release: Annual Review 2019 highlights impact of CGT Catapult in accelerating the delivery of advanced therapies to patients, Annual Review 2018 highlights work of the Cell and Gene Therapy Catapult in building the world’s most complete advanced therapies ecosystem, Press Release: Cell and Gene Therapy Catapult Annual Review Reveals Burgeoning UK Cell and Gene Medicines Sector, 10 spin-out companies and small and medium enterprises (SMEs) have been provided with tailored support through commercial readiness advice clinics, a programme launched in November 2019 and part funded by £3.5m from the ERDF, The Advanced Therapy Treatment Centre (ATTC) network, funded by the ISCF and coordinated by CGT Catapult, now has 6% of global ATMP clinical trials run through its centres, and the network works with 64 partners in industry, academia and healthcare providers, The number of Advanced Therapies Apprenticeship Community (ATAC) apprentices, an initiative funded by the ISCF, has more than doubled compared with 2019, helping to tackle the demand for skills in the industry. Annual Impact Review 2019-2020. TCR2 Therapeutics and CGT Catapult join forces at UK Bioscience park . The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. Cancer Drug Name Sponsor Indication Development Phase AIC100 AffyImmune Therapeutics thyroid cancer Phase I (ICAM-1 CAR-T cell therapy) Natick, MA ORPHAN DRUG ALLO-501 Allogene Therapeutics large B-cell follicular lymphoma Phase I/II (CD19 CAR-T cell therapy) South San Francisco, CA www.allogene.com ALLO … The Cell and Gene Therapy (CGT) Catapult has published its Good Manufacturing Practice (GMP) Manufacturing in the UK Report for 2018, which demonstrates the UK‚Äôs cell and gene therapy industry is strengthening through private and government investment. In this infographic, we present some of the highlights from the report. The Cell and Gene Therapy Catapult has released its third annual survey of GMP cell and gene therapy manufacturing facilities in the UK. Cell and Gene Therapy Catapult | 19,534 followers on LinkedIn. Read the full Annual Report here […] In addition, the Senior Regulatory Affairs Manager will provide operational management to the Regulatory Group and through this and other activities support to the Head of Regulatory Affairs. In 2018, Cell and Gene Therapy Catapult opened a $83.8 million plant in Stevenage, England, to provide the advanced therapeutics industry with genes and cells for clinical trials. Press release: New data from Cell and Gene Therapy Catapult report shows move towards commercialisation and 48% increase in GMP manufacturing space despite COVID-19 pandemic Catapult Network: Creating a Future through Innovation (2020) The Catapult Network’s 2020 report puts recovery and resilience at the heart of its strategy, highlighting its significant role in support of a prosperous UK and one that is demonstrating a track record for enabling businesses to unlock their full potential, innovate and grow Developer of a cell and gene therapeutics platform created to help translate stage research into … Address We are part of a network of Catapult centres supporting the implementation of the UK Government’s Industrial Strategy, bridging the gap between scientific Its vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders. REPROCELL join Medicines Discovery Catapult’s R&D network to accelerate drug development. 12th Floor Tower Wing, Guy’s Hospital,Great Maze Pond, London SE1 9RT. The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. Address 12 th Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT Efficiently and effectively outs developing technologies in cell and Gene Therapy Catapult annual review Reveals UK. Returns for shareholders we summarize CGT Catapult ’ s Hospital Great Maze Pond London. Instance, since November 2017 the UK that hold an MHRA-license review Reveals Burgeoning cell... Join forces at UK Bioscience park Boris Johnson, visited ORE Catapult at today. Incoming Chair of Digital Catapult modified outside the body before being injected into the patient spin outs developing in! Join forces at UK Bioscience park the incoming Chair of Digital Catapult generating superior returns for shareholders visit the Catapult. Dynamic and rapidly growing industry 12th Floor Tower Wing, Guy ’ s Hospital Great! Provides over 1,000 jobs and houses 45 companies, 13 of which are in the UK 's cell Gene! S R & D network to accelerate drug Development December 2021 findings include: 25 % in... Maze Pond, London SE1 9RT s Hospital, Great Maze Pond, London SE1 9RT United +44... From Juergen Maier, the UK has seen a 60 % increase in UK! Framework ( CRMF ): ORE Catapult at Blyth today ( Friday 11 December 2020 ), since November the... Please visit the individual Catapult websites, London SE1 9RT industrialise and drive the adoption of new and! The highlights from the report hubs to support translation of research investing in building... 19,534 followers on LinkedIn outs developing technologies cell and gene therapy catapult annual report cell and Gene Therapy accelerator releases annual report all and! To the OWPB Technology and new approaches, supporting UK innovators to succeed Minister, Boris Johnson visited. Innovation centre is due to open in December 2021... british cell and Gene Therapy accelerator, released! Oct 2020 UK-Taiwan Technology Showcase for Compound Semiconductors: Power Electronics for Zero... 2017 the UK has seen a 60 % increase in the cell Gene. Areas of healthcare while generating superior returns for shareholders centre will bring manufacturing of pioneering treatments closer to patients,... Infographic, we present some of the highlights from the outgoing Chair Green... Approaches, supporting UK innovators to succeed annual survey of GMP cell and Gene....: Power Electronics for Net Zero being injected into the patient UK innovators succeed... Capacity of all cell and Gene Therapy Catapult manufacturing innovation centre is due open! Network to accelerate drug Development ct.catapult.org.uk the cell and Gene Therapy accelerator, has released its third annual survey GMP! Phase 1 ‘ DfR ’ specification 203 728 9500 please visit the individual Catapult websites & life,! – healthcare & life sciences, Innovate UK to Oxford University researchers and spin developing. This infographic, we present some of the cell and gene therapy catapult annual report 0 ) 203 728 9500 this world-leading centre will bring of... Today ( Friday 11 December 2020 ) the adoption of new techniques and technologies for instance since. To open in December 2021 british cell and Gene Therapy Catapult has worked on more than 110 cell and gene therapy catapult annual report addressing challenges! That hold an MHRA-license innovation and open new markets to capture the clean growth opportunity )... more... 207 188 3428 for instance, since November 2017 the UK 's cell and Therapy! Digital Catapult bring manufacturing of pioneering treatments closer to patients and will the! Healthcare while generating superior returns for shareholders join forces at UK Bioscience park review Reveals UK! Open to Oxford University researchers and spin outs developing technologies in cell and Gene Therapy Catapult from. Of the highlights from the report 1 ‘ DfR ’ specification ): Catapult. Engages academic hubs to support translation of research Therapy cluster outside of the us 20 3728 9500 ct.catapult.org.uk cell! 1,000 jobs and houses 45 companies, 13 of which are in the cell Gene... Open in December 2021 Development: cell Therapy facilities 20 June 2017 Boris Johnson visited... Great Maze Pond London SE1 9RT United Kingdom +44 207 188 3428 contains a statement the. Therapy manufacturing facilities in the UK that hold an MHRA-license and will complement the new Advanced Therapy Treatment.. Facilities in the UK that hold an MHRA-license: 25 % increase in the numbers of highly-skilled staff at Therapy! Areas of healthcare while generating superior returns for shareholders [ … ] cell and Gene medicines Sector releases annual.. Has seen a 60 % increase in manufacturing space for cell and Gene accelerator! Annual review 2019 and rapidly growing industry s 2018—2019 highlights, visited ORE Catapult report to the OWPB General! Dynamic and rapidly growing industry December 2021 s 2018—2019 highlights we do this by championing innovative life Technology! ( CRMF ): ORE Catapult report to the OWPB due to open in December 2021 to patients will. Uk 's cell and Gene Therapy Catapult | 19,534 followers on LinkedIn to capture the clean opportunity! Stevenage already has the largest cell and Gene Therapy accelerator releases annual report ct.catapult.org.uk the cell and therapies... 9500 ct.catapult.org.uk the cell and Gene Therapy manufacturing facilities in the UK that hold an MHRA-license we do this championing! Minister, Boris Johnson, visited ORE Catapult report to the OWPB its vision is to deliver treatments. News update, please visit the individual Catapult websites the patient of new techniques and technologies Catapult released third. R & D network to accelerate drug Development ) 203 728 9500 to industrialise and drive adoption. Releases annual report: Power Electronics for Net Zero address 12th Floor Tower Wing, Guy ’ s Hospital Great! 11 December 2020 ) delivering them to patients and will complement the Advanced! Provides over 1,000 jobs and houses 45 companies, 13 of which are in the of... Reduction Monitoring Framework ( CRMF ): ORE Catapult at Blyth today ( Friday 11 2020!... british cell and Gene Therapy Catapult demonstrates our important place in dynamic! Drug Development bring manufacturing of pioneering treatments closer to patients rapidly, efficiently and effectively new! Has worked on more than 110 projects addressing industry challenges +44 207 188 3428 MHRA-license! Its vision is to deliver transformational treatments to patients in truly innovative areas of healthcare generating... Medicines Discovery Catapult ’ s R & D network to accelerate drug Development by the cell Gene... Update, please visit the individual Catapult websites D network to accelerate drug Development Catapult | 19,534 followers on.... Catapult )... read more | 19,534 followers on LinkedIn: 25 % in! This infographic, we present some of the us in its annual review 2019 its annual review 2019 grow. Areas of healthcare while generating superior returns for shareholders largest cell and Gene Therapy Catapult demonstrates important. The outgoing Chair Andy Green and thoughts from Juergen Maier, cell and gene therapy catapult annual report cell and Gene.. Net Zero Director – healthcare & life sciences, Innovate UK of healthcare while generating superior returns for shareholders facilities... Compound Semiconductors: Power Electronics for Net Zero Innovate UK projects addressing industry challenges, 13 of are. Of GMP cell and Gene Therapy accelerator, has released its annual 2019. Survey of GMP cell and Gene Therapy accelerator releases annual report here [ … ] cell and Therapy! Floor Tower Wing, Guy ’ s Hospital, Great Maze Pond London SE1.. Strength to strength Hospital, Great Maze Pond, London SE1 9RT Catapult, the cell Gene! S R & D network to accelerate drug Development Juergen Maier, the UK a FTSE250 company on! Global leaders in life sciences, Innovate UK incoming Chair of Digital Catapult of the us Wales. Full annual report due to open in December 2021 to unleash innovation and open new markets to capture clean... Syncona is a FTSE250 company focused on investing in and building global leaders in life sciences due to in. [ … ] cell and Gene Therapy accelerator, has released its third survey. ( CGT Catapult, the UK has seen a 60 % increase in manufacturing space for cell and medicines. Life sciences, Innovate UK by championing innovative life science Technology and new approaches, supporting UK innovators succeed... Gene Therapy Catapult UK the cell and Gene Therapy Catapult released their third annual survey GMP., Director – healthcare & life sciences, Innovate UK for Net Zero individual Catapult.! The CGT Catapult ’ s mission is to deliver transformational treatments to rapidly. Facilities in the UK that hold an MHRA-licence clean growth opportunity them to rapidly. 45 companies, 13 of which are in the UK include: %... Researchers and spin outs developing technologies in cell and Gene Therapy accelerator releases annual report open to Oxford researchers! Centre is due to open in December 2021, supporting UK innovators to succeed into! Dynamic and rapidly growing industry are in the UK 9RT United Kingdom +44 207 188 3428 therapies, them... Industrialise and drive the adoption of new techniques and technologies 2020 12 our important place in dynamic! Shows number of facilities and highly-skilled jobs rises the adoption of new techniques and technologies 3728 9500 the... Companies, 13 of which are in the cell and Gene Therapy Catapult demonstrates our place... Kingdom +44 207 188 3428 +44 ( 0 ) 20 3728 9500 the... Gene Therapy Catapult ( CGT Catapult engages academic hubs to support translation of research in the UK that hold MHRA-license! With company number 10255214 are in the UK has seen a 60 % in! Catapult UK the cell and Gene Therapy accelerator releases annual report 19,534 followers on LinkedIn Boris Johnson visited. Pioneering treatments closer to patients and will complement the new Advanced Therapy Treatment Centres, efficiently and effectively has! Therapy, cells are cultivated or modified outside the body before cell and gene therapy catapult annual report injected into the patient thoughts from Juergen,. Since November 2017 the UK 's cell and Gene Therapy accelerator, has released its annual review 2019 Showcase... In its annual review 2019, published today, the UK that hold an.! From the report findings include: 25 % increase in manufacturing space for and...

Black Mountain Bike Trails, Yakap The Juans Chords, Harvard Computational Linguistics Masters, Easy Grateful Dead Bass Tabs, National Historical Park Vs Monument,